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Abstract
Background: The identification of a BRCA1 or BRCA2 mutation in familial breast cancer kindreds
allows genetic testing of at risk relatives. However, considerable controversy exists regarding the
cancer risks in women who test positive for the family mutation.
Methods: We reviewed 385 unrelated families (223 with BRCA1 and 162 with BRCA2 mutations)
ascertained through two regional cancer genetics services. We estimated the penetrance for both
breast and ovarian cancer in female mutation carriers (904 proven mutation carriers – 1442 females
in total assumed to carry the mutation) and also assessed the effect on penetrance of mutation
position and birth cohort.
Results: Breast cancer penetrance to 70 and to 80 years was 68% (95%CI 64.7–71.3%) and 79.5%
(95%CI 75.5–83.5%) respectively for BRCA1 and 75% (95%CI 71.7–78.3%) and 88% (95%CI 85.3–
91.7%) for BRCA2. Ovarian cancer risk to 70 and to 80 years was 60% (95%CI 65–71%) and 65%
(95%CI 75–84%) for BRCA1 and 30% (95%CI 25.5–34.5%) and 37% (95%CI 31.5–42.5%) for BRCA2.
These risks were borne out by a prospective study of cancer in the families and genetic testing of
unaffected relatives. We also found evidence of a strong cohort effect with women born after 1940
having a cumulative risk of 22% for breast cancer by 40 years of age compared to 8% in women
born before 1930 (p = 0.0005).
Conclusion: In high-risk families, selected in a genetics service setting, women who test positive
for the familial BRCA1/BRCA2 mutation are likely to have cumulative breast cancer risks in keeping
with the estimates obtained originally from large families. This is particularly true for women born
after 1940.
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Since the identification of the BRCA1 [1] and BRCA2 [2]
genes a great deal of debate has focussed on the issue of
breast and ovarian cancer risk associated with mutations
in these genes. It is clear that calculated cancer risks are
dependent on the method of ascertainment of the families
studied. Thus, breast cancer risks in large familial breast
cancer kindreds with BRCA1/BRCA2 mutations are sub-
stantially higher than risks derived from population based
studies [3,7,8]. In the high-risk families that recruited to
the Breast Cancer Linkage Consortium (BCLC) cohort,
BRCA1 and BRCA2 mutations were estimated to cause a
cumulative lifetime risk of breast cancer at age 70 years of
85–87% and 77–84% respectively [3,7,8]. However, esti-
mates of breast cancer risks to age 70 years of age derived
from previous population based studies to date are much
lower at 28–60% [4-6] for BRCA1, and lower still for
BRCA2. It has been suggested that even these studies may
overestimate the effect of the BRCA1/2 mutation alone
[9]. Whilst there is some evidence of variation of cancer
risk by position of mutation within each gene [10-12],
more variation occurs between families with the same
mutation. Therefore it is likely that a substantial propor-
tion of the breast cancer risk in strong familial clusters
with a BRCA1/2 mutation (the group of families that are
usually seen by a Cancer Genetics Service), might be con-
tributed to by modifier genes [13]. Optimum clinical
practice requires, that the cancer risks provided to families
undergoing genetic testing are appropriate to the setting
in which the mutation was detected. To determine the
most appropriate risks for women attending clinical can-
cer genetics services we determined the cumulative risks of
breast and ovarian cancer for 385 families with patho-
genic BRCA1/2 mutations identified in North West and
Central England covering a population of 10 million.
Methods
Index cases and relatives
Breast and ovarian cancer families have been tested for
BRCA1/2 mutations (using a whole gene analysis includ-
ing a test for large deletions) since 1996 in the overlap-
ping regions of Manchester and Birmingham in mid-
north England. All genetic testing is undertaken with
informed consent and consent is also taken to confirm
cancer diagnosis. The study was carried out with Local
Ethical committee approval. Women who attend the spe-
cialist genetic clinics in these regions with a family history
of breast/ovarian cancer have a detailed family tree elic-
ited with all first, second and if possible third degree rela-
tives recorded. If a BRCA1/2 mutation is identified, further
extensive attempts are made to ensure that all individuals
at risk of inheriting the family mutation are represented
on the pedigree. All cases of breast or abdominal cancers
are confirmed by means of hospital/pathology records,
from the Regional Cancer Registries (data available from
1960) or from death certification. Once a family specific
pathogenic BRCA1/2 mutation is identified predictive
testing is offered to all blood relatives. Where possible all
affected women with breast/ovarian cancer are tested to
establish the true extent of BRCA1/2 involvement in the
family. In many large families it is possible to establish
"obligate" gene carriers by testing for the same mutation
in different branches of the family, thereby establishing
that intervening relatives carry the same mutation.
All female BRCA1/2 mutation carriers identified were
included in this study, and their details, those of all tested
relatives and first-degree untested female relatives were
entered onto a Filemaker Pro 5 database. The initial indi-
vidual in which a mutation was identified was designated
the "index" case, with all other individuals being classified
as to their position in the pedigree compared to a proven
mutation carrier. All women reaching 20 years were
entered if untested for a mutation. The exception was
mothers of a mutation carrier when it was clear that the
mutation was paternally inherited. 385 index cases were
studied and from these extended pedigrees information
on a total of 2466 females was collected. Information was
entered on date of birth, date of last follow up, breast can-
cer status, ovarian cancer status, dates of diagnoses and
date of death (if applicable), gene mutation carried in the
family, their relationship to a known mutation carrier and
their mutation status and date at which testing took place.
The proportions of unaffected first-degree relatives (FDRs)
testing positive or negative was derived for each age
cohort. Figures from this were used to estimate the pro-
portion of untested relatives that were likely to test posi-
tive in each age group. The proportion of untested FDRs
with breast or ovarian cancer that were likely to test posi-
tive was similarly estimated from testing that had taken
place in each family. Penetrance analysis was performed
by including all mutation positive individuals and appro-
priate numbers of untested FDRs on a proportional basis.
Kaplan Meier curves were derived for breast and ovarian
cancer incidence for each gene and by dividing each gene
into the previously identified ovarian cancer cluster region
(OCCR): exon 11 (nucleotides 2401–4190) for BRCA1
and exon 11 (nucleotides 3035–6629) for BRCA2. For
BRCA1 we used the nucleotide range identified by the
BCLC [11], although this is not traditionally called an
OCCR it is the region published as having the greatest pro-
portional risk of ovarian cancer. Individuals were cen-
sored at age of death, age of last follow up, age at
appropriate cancer or age at appropriate risk reducing sur-
gery (oophorectomy for ovarian cancer, mastectomy and
oophorectomy for breast cancer). The Manchester scoring
system was used to assess the strength of the breast/ovar-
ian cancer history [14]. This system was devised to assess
the likelihood of a BRCA1/2 mutation and scores breastPage 2 of 9
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higher score the younger the age at diagnosis [14]. A com-
bined score of 20 reflects a 20% likelihood of identifying
a BRCA1/2 mutation.
Results
The 385 families consisted of 223 apparently unrelated
BRCA1 and 162 BRCA2 families. Mutations were spread
throughout the BRCA1 and BRCA2 genes with the com-
monest mutation being the Jewish exon 2 185 DelAG (31
families). There were also 20 families with single or mul-
tiple exon deletions or duplications in BRCA1 and 6 in
BRCA2. These families contained 904 proven female
mutation carriers (526 in BRCA1; 378 in BRCA2). There
were 992 female FDRs of unknown mutation status: 554
in BRCA1; 438 in BRCA2 kindreds. Of these 244 had been
diagnosed with breast cancer, 88 with ovarian cancer and
14 with both. 21/206 (10%) FDRs with breast cancer
tested negative for the family mutation, but only 1/101
FDRs with ovarian cancer. The age distribution of the
breast cancer cases testing negative for the mutation was
identical to those testing positive. We therefore assumed
that every tenth untested FDR with breast cancer (only)
was negative for the mutation in each gene. All 21 individ-
uals testing negative for the family mutation were also
negative for the 1100delC mutation in CHEK2. As 99% of
the ovarian cancers tested were positive we assumed that
all FDRs with ovarian cancer were positive. The results for
predictive testing of unaffected females for each gene are
shown in Table 1. We assumed that similar proportions of
untested unaffected female relatives would test positive
for each gene. We therefore stratified these relatives by age
and excluded an increasing proportion of the relatives as
indicated for each age group. For the age group of 60 years
and over we assumed that 10% would be positive for
BRCA1 and 20% for BRCA2.
The proportion testing positive for each gene with Man-
chester scores [14] above and below 20 and 23 are pre-
sented in Table 2. This shows a substantial effect of cancer
burden for BRCA2 with high-risk families (scores above
20 points) having a much lower proportion of positive
predictive tests after 50 years.
Overall, of the FDRs of unknown mutation status, 92/92
with ovarian cancer, 220/244 with breast cancer and 234/
648 unaffected FDRs were included in the analysis. In
total this amounted to 839 actual and presumed carriers
for BRCA1 and 603 actual and presumed carriers for
BRCA2. There were 243/839 (29%) BRCA1 individuals
with ovarian cancer compared to 64/603 (11%) female
BRCA2 carriers. 411/839 (49%) BRCA1 carriers and 355/
603 (59%) BRCA2 carriers had developed breast cancer.
Penetrance estimates for each gene are shown (Table 3;
Figures 1, 2) for breast and ovarian cancer. The curves
were remarkably similar for each gene, with breast cancer
penetrance to 70 and 80 years of 68% (95%CI 65–71%)
and 79.5% (95%CI 75–84%) for BRCA1 and 74%
(95%CI 71–77%) and 88% (95%CI 85–91%) for BRCA2.
Ovarian cancer risk to 70 and 80 years was 60% (95%CI
65–71%) and 65% (95%CI 75–84%) for BRCA1 and 30%
(95%CI 25.5–34.5%) and 37% (95%CI 31.5–42.5%) for
BRCA2. The penetrance for ovarian cancer was signifi-
cantly higher for BRCA1 (p < 0.0001), but breast cancer
incidence for BRCA2 was borderline significantly higher
than for BRCA1 (p = 0.09). Indeed breast cancer pene-
trance estimates for BRCA2 after 60 years were signifi-
cantly higher as was overall penetrance including the
index case (p = 0.02). There was no significant effect of
ovarian cancer cluster regions (OCCR, nucleotides 2401–
4190 BRCA1 and nucleotides 3035–6629 in BRCA2) for
either gene with lifetime ovarian cancer risks (to 80 years)
of 65% for 573 BRCA1 carriers outside the OCCR and
70% for 266 women with mutations within the OCCR (p
= 0.18). Similarly there was no effect of position for
BRCA2 with lifetime risks of 37% for 373 BRCA2 carriers
outside the OCCR and 41% for 230 BRCA2 women with
OCCR mutations (p = 0.17). There was a 10% higher
Table 1: Proportion of living unaffected FDR females undertaking presymptomatic predictive genetic testing by gene and age cohort.
Predictive 
test result 
By age
BRCA1 
+ve
BRCA1-ve Number 
positive 
BRCA1
BRCA1 
untested
BRCA2 
+ve
BRCA2-ve Number 
positive 
BRCA2
BRCA2 
untested
Proportion 
positive 
BRCA1 
assumed
Proportion 
positive 
BRCA2 
assumed
18–30 yrs 28 34 28/62 
(45%)
41 18 19 18/37 
(48%)
34 50% 50%
30–39 yrs 51 42 51/93 
(55%)
78 50 41 50/91 
(55%)
64 50% 50%
40–49 22 44 22/66 
(33%)
57 34 27 34/61 
(56%)
49 33% 50%
50–59 10 19 10/29 
(34%)
43 14 21 14/35 
(40%)
59 33% 40%
60+ 2 24 2/26 (8%) 60 4 19 4/23 (17%) 69 10% 20%
Total 113 163 103/266 279 110 127 110/240 247Page 3 of 9
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those outside the BRCA2 OCCR, although lifetime risk
was little different at 90% and statistical significance was
not reached (p = 0.07). No such difference was seen for
BRCA1 with virtually identical incidence curves (p =
0.25). DCIS was included as breast cancer. However, this
only amounts to 1% of BRCA1 breast cancers and 2% for
BRCA2. It is likely that nearly all of these would have
become invasive as only 1/16 occurred after 60 years of
age. Tamoxifen is not licensed in the UK for prevention.
Only 23 mutation carriers took tamoxifen as part of the
IBIS1 prevention trial and this is unlikely to have materi-
ally changed the penetrance estimates.
An estimate for breast cancer penetrance was also made
for each 10–20 year birth cohort. A highly significant dif-
ference was identified with those born after 1960 having
a breast cancer risk to 40 years of age of 40% compared to
only 7.5% for those with a year of birth between 1900 and
1920 (Figure 3: p < 0.00001). However, after exclusion of
the index case the cumulative risk to 40 years dropped to
between 21–23% for the birth cohorts after 1940. This
was, nonetheless still a highly significant trend (p =
0.0005). After exclusion of the index case there was no sig-
nificant birth cohort effect observed for ovarian cancer (p
= 0.086). To assess the earlier age at breast cancer diagno-
sis on life expectancy we carried out a Kaplan-Meier sur-
vival analysis on the birth cohorts, again excluding the
index case. There was no significant difference in survival
from birth (Table 4; log rank df 6, p = 0.07), although
there was a trend to better survival in the earlier birth
cohorts. Indeed if the index case was included 21/83
(25%) index cases post birth year 1960 had died by 45
years of age, equivalent to a cumulative mortality of 35%
to that age.
Breast cancer incidence was also assessed after family
ascertainment. Incidence figures for breast/ovarian cancer
are shown in Table 5. These reflect the incidence in unaf-
Table 2: Proportion of predictive tests positive in unaffected 
FDR women >50 years of age by family Manchester score for 
each gene
Manch score predictives Above or = Below
(score) % positive % positive
BRCA2 >50 (23) 9/37 (24%) 9/24 (37.5%)
BRCA2 >50 (20) 10/44 (23%)* 8/17 (47%)*
BRCA1 >50 (23) 7/33 (21%) 5/20 (20%)
BRCA1 >50 (20) 8/39 (20.5%) 4/14 (29%)
*chi square for difference 3.48; p = 0.07
Breast cancer cumulative incidence by gene (BRCA1 or BRCA2)Figure 1
Breast cancer cumulative incidence by gene (BRCA1 or BRCA2).
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low up was censored at the time of risk reducing surgery
(oophorectomy/mastectomy). As the index case was used
to identify the mutation usually on surveillance the inci-
dence rates for these cases are artificially high. Excluding
the index cases there was an incidence of 2.5–2.7 per
thousand for breast cancer in proven carriers. Even includ-
ing 40% of the follow up time and 80% of the breast can-
cers from the FDR unknown category (Tables 1 and 2),
this still gave an annual incidence of breast cancer of
1.98% for both BRCA1/2 mutation carriers (38/1917; 35/
1763.6). An annual rate of 2% averaged over the risk
period of 30–79 years would if anything indicate a higher
risk than those indicated by the Kaplan-Meier analysis.
Discussion
We present data on a large cohort of women identified as
carriers or presumed carriers of BRCA1 and BRCA2 muta-
tions in a large proportion of the UK population. The pen-
etrance estimates derived from these women are very
similar to those derived from the BCLC cohort of high-risk
families with lifetime risks of breast cancer of close to 85%
for both genes [3,7,8]. The estimate of ovarian cancer was
also very similar with risks to 70 years of 60% for BRCA1
carriers and 33% as opposed to 27% [3] for BRCA2 carri-
Ovarian cancer cumulative incidence by gene (BRCA1 or BRCA2)Figure 2
Ovarian cancer cumulative incidence by gene (BRCA1 or BRCA2).
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Table 3: Penetrance for breast and ovarian cancer by age for BRCA1 and BRCA2.
Cancer risk to age BRCA1 Breast (se) BRCA2 Breast (se) BRCA1 Ovary (se) BRCA2 Ovary (se)
30 2% 2.5% 0 0
40 16.5%(0.015) 17%(0.019) 3% (0.007) 0
50 48%(0.023) 42%(0.027) 21%(0.02) 4% (0.012)
60 55%(0.027) 63%(0.031) 40%(0.024) 16% (0.03)
70 68% (0.033) 75%(0.033) 60% (0.037) 30% (0.046)
80 79.5% (0.04) 88%(0.037) 65% (0.042) 37% (0.056)
se-standard errorPage 5 of 9
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BMC Cancer 2008, 8:155 http://www.biomedcentral.com/1471-2407/8/155ers. It is possible that the higher overall breast cancer esti-
mates for BRCA2 were related to competing mortality
from ovarian cancer. Many risk factors for breast and ovar-
ian cancer are similar (early menarche, late menopause,
nulliparity) and women with these may have died from
ovarian cancer before they developed breast cancer. This
effect would be more prominent for BRCA1 and would
potentially explain the higher breast cancer penetrance for
BRCA2. The ratio of those testing positive:negative for the
BRCA mutation whilst still unaffected also gives support
to high penetrance. Of those women without an affected
daughter, <10% of those aged over 60 years, tested posi-
tive for BRCA1 and <20% for BRCA2. The figures over 60
years are, nonetheless based on small numbers. The ear-
lier drop in positive:negative ratio for BRCA1 almost cer-
tainly represents a higher combined risk of both breast
Cumulative risk of breast cancer by age cohort for BRCA1 and BRCA2 combined after exclusion of the index caseFigure 3
Cumulative risk of breast cancer by age cohort for BRCA1 and BRCA2 combined after exclusion of the index 
case. Risk to 40 years: Group 1 (birth year <1900; n = 45) 4%; Group 2 (1900–1920; n = 154) 8%; Group 3 (1920–1930; n = 
154) 10%; Group 4 (1930–1940; n = 124) 17%; Group 5 (1940–1950; n = 162) 21%; Group 6 (1950–1960; n = 265) 23%; 
Group 7 (1960+; n = 276) 22%. Log rank (df 6) 153; p = 0.0005.
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Table 4: Survival analysis from birth, BRCA1 and BRCA2 combined for each birth cohort, index case excluded
% died from 
birth to age
<1900 (n = 45) 1900–1919 
(n = 154)
1920–1929 
(n = 154)
1930–1939 
(n = 124)
1940–1949 
(n = 158)
1950–1959 
(n = 162)
1960+ (n = 276)
45 years 15% 14% 17% 17% 21% 15% 17%
60 years 42% 56% 57% 62% 56%
70 years 73% 74% 77% 85%
Log Rank 11.53 df6 p = 0.07Page 6 of 9
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feature is shown in Table 2. The typical families tested in
our centre have a Manchester score of 20+ reflecting mul-
tiple early onset breast and/or ovarian cancer in the fam-
ily. The less "high" risk clusters as evidenced by lower
Manchester scores had a higher proportion testing posi-
tive >50 years. This suggests that Manchester score could
be used as a bench-mark to predict penetrance particularly
in BRCA2 families. Whilst all attempts to assess pene-
trance have their inherent biases and assumptions this
cannot be said of the results of presymptomatic testing.
The only potential bias would be if women had an inkling
that they would test positive or negative prior to coming
forward. This is not borne out by our results particularly
accounting for Manchester score.
The previously reported positional effect of mutations for
both BRCA1 and BRCA2 is not borne out by our analysis.
No substantial effect of increased risk of ovarian cancer
was seen in the respective ovarian cluster regions of each
gene and only a borderline significant reduction of breast
cancer risk was seen for BRCA2. Much of the OCCR asso-
ciation has been based on ratios of breast to ovarian can-
cer [10] or on the presence or not of ovarian cancer in the
family [11]. Even this reliance on the presence of ovarian
cancer for BRCA2 has been questioned by the report of
58% of BRCA2 related ovarian cancer families having
mutations outside the OCCR [12]. Although the BCLC
study on BRCA1 positional effect [10] included 356 fami-
lies compared to our 223 families no absolute estimate of
penetrance was made. Whilst the breast cancer incidence
was lower in the central portion of the gene (nucleotides
2401–4190) (RR 0.71) in their analysis it was not possible
to derive absolute risk figures for each portion of the gene.
Additionally it is likely that our more extensive testing of
unaffected relatives may provide a more accurate overall
picture as reported here. Accurate estimates of cancer risk
are essential for families and individuals undertaking
genetic testing. Based on our analysis, it is questionable
whether any account should be taken of the OCCR in each
gene or indeed any substantial positional effect in genetic
counselling.
It is also clear that for individuals undertaking predictive
genetic testing in the context of families ascertained from
cancer genetic clinics as opposed to population testing
that risk figures similar to those derived in our study or the
BCLC is quoted in our own clinics and we recommend
that penetrance estimates are derived for the population
being counselled. Our data are nonetheless at variance to
a similar analysis carried out in North America [15]. A
series of 1948 families were tested for mutations in
BRCA1/2 in eight centres. 283 families with BRCA1 muta-
tions were identified and 143 in BRCA2. The authors used
statistical modelling to arrive at penetrance figures by 70
years of 46% (95%CI 39–54%) for BRCA1 and 43%
(95%CI 36–51%) for BRCA2. The authors did not appear
to take advantage of any further testing of relatives in the
family. Whilst they corrected for potential ascertainment
bias, they did not allow for the effects of modifier genes in
these families and purely looked at attributable risk from
BRCA1 and BRCA2 mutations alone. This was based on
the apparent lack of heterogeneity in another study of Jew-
ish families from North America [16]. What is particularly
concerning is the risk attributed to "non mutation carri-
ers" to 70 years. A figure of 5% as a general population risk
for breast cancer may have been correct 20–30 years ago,
but is certainly not the risk faced by women in the US or
the UK today. Breast cancer risk to age 70 is 7.6% in the
UK [17] and nearer 8% in the US. A correction for this dif-
ference might give penetrance figures of nearer 74% for
BRCA1 and 69% for BRCA2. The decision not to include
any adjustment in these families for the effects of modifier
genes is questionable. The difference in penetrance
Table 5: Breast and ovarian cancers occurring after the family was referred to the genetics centre.
Number of 
women
Years f/u 
(Breast ca)
Cancers Rate (%/Year) Number of 
women
Years f/u 
(ovarian ca)
Cancers Rate
BRCA1 Carriers 256 1522.33 65 4.27 403 2256.13 37 1.64
BRCA1 FDR 
unknown
341 1988.07 13 0.65 355 2049.42 6 0.29
BRCA1 Index 87 399.49 37 9.3 194 977.35 24 2.5
BRCA1 Carriers 
less index
159 1122.33 28 2.5 209 1278.78 13 1.01
BRCA2 Carriers 210 1210.41 61 5.0 363 2235.14 12 0.54
BRCA2 FDR 
unknown
324 2096.93 12 0.57 345 2187.04 4 0.19
BRCA2 Index 66 285.59 36 12.6 175 966.69 9 0.93
BRCA2 Carriers 
less index
144 924.82 25 2.7 363 1268.45 3 0.24
Censored if affected with relevant cancer prior to date of referral and at RRS, relevant cancer diagnosis, or date of last follow up.
The index case was used to identify the mutation. Women were censored at time of risk reducing surgery.Page 7 of 9
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strongly suggests the presence of additional genetic factors
in high-risk families. We have recently reported that those
testing negative for a family BRCA mutation are still at 3-
fold relative risk of breast cancer [13]. This phenocopy
effect was also seen in the Iceland data for their founder
BRCA2 mutation, although to a lesser extent given the
strong population based element of their analysis [18].
However, it is possible that modifier genes are more prev-
alent in some populations and that penetrance in North
America is less affected by modifier genes than in the UK.
The presence of these modifier alleles is now indisputable
from recent genome wide association studies [19-21].
A potential criticism of our study is that we have not taken
enough account of ascertainment bias and that additional
adjustment maybe necessary beyond excluding the index
case. An analysis using these adjustments was carried out
in the North American study [15] and recent reports from
the Cambridge group [22]. These studies did not take into
account the widespread testing of relatives and as
explained above the American study deliberately excluded
any effect other than of the BRCA1/2 mutation. Whilst it
is clearly interesting to know the effect of BRCA1/2 alone,
women undergoing testing will want to know what their
own specific risk of breast and ovarian cancer are, includ-
ing that contributed by other potential "modifier" genes
in their family. We must also acknowledge that confi-
dence intervals in table 3 should also be wider due to forc-
ing the data on unknown FDRs into a known category.
The high-risk women testing positive is also supported by
the prospective part of our study. The 2–2.7% annual risk
demonstrated is equivalent to the highest risk in a 10-year
period (23% BRCA1; 30% BRCA2-Table 3). Although
most of the breast cancers were detected by screening,
only one was detected at a prevalence mammogram.
These follow up risks are also supported by a similar fol-
low up study in the Netherlands where 8 breast cancers
occurred in 63 mutation carriers with a calculated annual
risk of 2.5% [23].
Our own study and recent analyses from North America
and Iceland demonstrate that women in the most recent
birth cohort have a substantially higher risk of developing
breast cancer than past cohorts [16,18]. The incidence of
breast cancer in BRCA2 carriers has risen 4 fold in 80 years
in Iceland (as has breast cancer in the general population)
and we have observed a similar increase from <10% risk
by 40 years in those born before 1930 to a 40% risk on
those born after 1960, although this was less significant
after allowing for ascertainment bias. It is, therefore, inap-
propriate to quote risks as low as 43–46% (based on pop-
ulation studies) for lifetime breast cancer risk to women
in their twenties or early thirties if they test positive for a
mutation in a high-risk family. Another potential effect of
earlier breast cancer might be a reduction in life expect-
ancy. With increasing survival from birth in the general
population and improved survival from diagnosis of
breast cancer we might have expected to see improved life
expectancy. However, it would appear that these elements
almost completely cancel each other out and there is no
evidence for improved survival from birth in modern
BRCA birth cohorts.
When discussing the higher risks of breast cancer in recent
generations, it is nonetheless important to couch any dis-
cussion on risk in terms of future prospects for risk reduc-
tion by preventive measures. Increasing numbers of
women are opting for risk reducing surgery particularly
early RRO, which will substantially reduce the risk of both
breast and ovarian cancer [24]. It is also likely that new
treatments or substantial changes from the Western life-
style may have a sufficient effect to help in risk manage-
ment in the future.
Conclusion
We believe our results show that when counselling
women on their risks of breast and ovarian cancer if they
carry a family BRCA1/2 mutation the risks should reflect
the context of cancer in their family and not just an aver-
age risk from possibly over-corrected penetrance estimates
from population studies. Indeed a recent review in a pres-
tige journal quoted "headline" risks for BRCA2 of only
40% and 8% for breast and ovarian cancer to 80 years
[25]. Understandably many clinicians and counsellors
may quote these risks. The use of family cancer burden in
adjusting risks to carriers is already used in the BOADI-
CEA programme [26] and the Manchester score could also
be used as a bench mark of where in the range of 40–90%
breast cancer risk a women should be steered, especially
for BRCA2.
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